← Leaderboards
Junxuan Lu
Amc Cancer Research Center
$11,268,028
Attributed
$13,105,416
Total exposure
11
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$13,105,416 · 11
By mechanism
R01$11,756,010 · 7
R21$1,116,913 · 3
R29$232,493 · 1
Top collaborators
- Yibin Deng4 shared
- Monika Joshi4 shared
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsMalignant Neoplasm Of ProstateProstateIn VivoApoptosisAndrogensGrowthChemopreventive AgentAdverse EffectsProstate CarcinogenesisCell Culture TechniquesCarcinogenesisCessation Of LifePreventOralPreventionTransgenic OrganismsOrganBaseCancer ChemopreventionMediatingFuturePathway InteractionsSignal Transduction
Grant awards (44)
Early clinial trials for Angelica herbal supplements for prostate cancer interception$1,175,356
R01 · FY2025 · CA · contact PI
Early clinial trials for Angelica herbal supplements for prostate cancer interception$558,295
R01 · FY2024 · CA · contact PI
Early clinial trials for Angelica herbal supplements for prostate cancer interception$575,924
R01 · FY2023 · CA · contact PI
Early clinial trials for Angelica herbal supplements for prostate cancer interception$623,285
R01 · FY2022 · CA · contact PI
Translational development studies of a novel combination therapy for castration-resistant prostate cancer$162,680
R21 · FY2019 · CA · contact PI
Translational development studies of a novel combination therapy for castration-resistant prostate cancer$214,380
R21 · FY2018 · CA · contact PI
PREVENTION OF PROSTATE CARCINOGENESIS BY NEXT-GENERATION SELENIUM$203,639
R01 · FY2018 · CA · contact PI
PREVENTION OF PROSTATE CARCINOGENESIS BY NEXT-GENERATION SELENIUM$90,971
R01 · FY2017 · CA · contact PI
Mechanisms of prostate cancer prevention by Korean Angelica$431,056
R01 · FY2016 · AT · contact PI
PREVENTION OF PROSTATE CARCINOGENESIS BY NEXT-GENERATION SELENIUM$332,401
R01 · FY2016 · CA · contact PI
PREVENTION OF PROSTATE CARCINOGENESIS BY NEXT-GENERATION SELENIUM$319,073
R01 · FY2015 · CA · contact PI
Mechanisms of prostate cancer prevention by Korean Angelica$281,746
R01 · FY2015 · AT · contact PI
Mechanisms of prostate cancer prevention by Korean Angelica$130,912
R01 · FY2015 · AT · contact PI
Mechanisms of prostate cancer prevention by Korean Angelica$100,000
R01 · FY2015 · AT · contact PI
Mechanisms of prostate cancer prevention by Korean Angelica$409,525
R01 · FY2014 · AT · contact PI
PREVENTION OF PROSTATE CARCINOGENESIS BY NEXT-GENERATION SELENIUM$309,436
R01 · FY2014 · CA · contact PI
Prostate cancer chemoprevention by penta-galloyl-glucose$294,807
R01 · FY2014 · CA · contact PI
Mechanisms of prostate cancer prevention by Korean Angelica$409,525
R01 · FY2013 · AT · contact PI
PREVENTION OF PROSTATE CARCINOGENESIS BY NEXT-GENERATION SELENIUM$344,401
R01 · FY2013 · CA · contact PI
Prostate cancer chemoprevention by penta-galloyl-glucose$1
R01 · FY2013 · CA · contact PI
Mechanisms of prostate cancer prevention by Korean Angelica$434,941
R01 · FY2012 · AT · contact PI
Prostate cancer chemoprevention by penta-galloyl-glucose$303,925
R01 · FY2012 · CA · contact PI
Prevention of PTEN deletion driven prostate cancer by selenium$165,844
R21 · FY2012 · CA
Prostate cancer chemoprevention by penta-galloyl-glucose$306,945
R01 · FY2011 · CA · contact PI
Methyl-selenium for prostate cancer chemoprevention$273,686
R01 · FY2011 · CA · contact PI
Prevention of PTEN deletion driven prostate cancer by selenium$199,013
R21 · FY2011 · CA · contact PI
An Oriental Herbal CAM modality for Prostate Cancer Chemoprevention$170,713
R21 · FY2011 · AT · contact PI
Prostate cancer chemoprevention by penta-galloyl-glucose$316,438
R01 · FY2010 · CA · contact PI
Methyl-selenium for prostate cancer chemoprevention$286,900
R01 · FY2010 · CA · contact PI
An Oriental Herbal CAM modality for Prostate Cancer Chemoprevention$204,283
R21 · FY2010 · AT · contact PI
Prostate cancer chemoprevention by penta-galloyl-glucose$316,438
R01 · FY2009 · CA · contact PI
Methyl-selenium for prostate cancer chemoprevention$286,900
R01 · FY2009 · CA · contact PI
Methyl-selenium for prostate cancer chemoprevention$286,900
R01 · FY2008 · CA · contact PI
Methyl-selenium for prostate cancer chemoprevention$282,636
R01 · FY2007 · CA · contact PI
Selenium and prostate cancer apoptosis pathways$233,253
R01 · FY2007 · CA · contact PI
Methyl selenium regulation of Angiogenic switch Mech$260,726
R01 · FY2006 · CA · contact PI
Selenium and prostate cancer apoptosis pathways$240,219
R01 · FY2006 · CA · contact PI
Methyl selenium regulation of Angiogenic switch Mech$267,000
R01 · FY2005 · CA
Selenium and prostate cancer apoptosis pathways$246,000
R01 · FY2005 · CA
Methyl selenium regulation of Angiogenic switch Mech$267,000
R01 · FY2004 · CA
Selenium and prostate cancer apoptosis pathways$266,500
R01 · FY2004 · CA
Methyl selenium regulation of Angiogenic switch Mech$289,250
R01 · FY2003 · CA
ROLE RAS/MAPK PATHWY IN MAM CANC PROMOT BY LINOLEIC ACID$117,935
R29 · FY2001 · CA
ROLE RAS/MAPK PATHWY IN MAM CANC PROMOT BY LINOLEIC ACID$114,558
R29 · FY2000 · CA